Modus Therapeutics approved for listing - first day of trading is July 22, 2021
STOCKHOLM, SWEDEN - July 20, 2021: Modus Therapeutics Holding AB (“Modus Therapeutics” or “the Company”) announces that the Company has received approval for listing on the Nasdaq First North Growth Market (“First North”). Modus Therapeutics also announces that the Swedish Companies Registration Office has registered the Company's recently completed issue of units and that the first day for trading is on Thursday, July 22, 2021. The Company's shares will be traded under the short name “MODTX” and ISIN code SE0015987904 and warrants of series TO 1 are traded under the short name "MODTX TO 1"